search
Back to results

Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin

Primary Purpose

Helicobacter Pylori Infection

Status
Recruiting
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Levofloxacin
tinidazole
Sponsored by
Shandong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Helicobacter Pylori Infection focused on measuring Allergic, Penicillin, Helicobacter pylori, Eradication, Tetracycline

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18-70 with H. pylori infection.
  • Patients Allergic to Penicillin.

Exclusion Criteria:

  • Patients with previous H. pylori eradication therapy.
  • Patients treated with Histamine-receptor antagonist, proton pump inhibitor, bismuth and antibiotics in the previous 4 weeks.
  • Patients with gastrectomy, acute gastrointestinal bleeding and advanced gastric cancer.
  • Patients with known or suspected allergy to study medications.
  • Currently pregnant or lactating.
  • Inability to provide informed consent

Sites / Locations

  • Qilu hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

levofloxacin-tetracycline-containing quadruple group

tinidazole-tetracycline-containing quadruple group

Arm Description

patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d

patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.

Outcomes

Primary Outcome Measures

Eradication rates in 2 groups
Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.

Secondary Outcome Measures

The rate of improving dyspepsia symptoms after Helicobacter pylori eradication
Dyspepsia symptoms will be measured using a 8-point Likert scale, and patients rate their symptoms from 0 (none) to 8 (severe) before and after the Helicobacter pylori eradication.
The rate of adverse events happening
Similarly, adverse events will also be measured by the Likert scale.
The rate of good compliance
Patients taken over 90% of drugs are considered to have a good compliance.

Full Information

First Posted
October 8, 2019
Last Updated
November 17, 2021
Sponsor
Shandong University
search

1. Study Identification

Unique Protocol Identification Number
NCT04122287
Brief Title
Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
Official Title
Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2019 (Actual)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shandong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess and compare the effectiveness of levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple regimens for the primary treatment of Helicobacter pylori infection in patients allergic to penicillin.
Detailed Description
Helicobacter pylori(H.pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H.pylori eradication is an effective approach to reduce the incidence of those pathologies.However,Helicobacter pylori eradication is a challenge in patients allergic to penicillin. Therefore, the investigators aim to assess and compare the effectiveness of levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple regimens for the primary treatment of Helicobacter pylori infection in patients allergic to penicillin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Helicobacter Pylori Infection
Keywords
Allergic, Penicillin, Helicobacter pylori, Eradication, Tetracycline

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
levofloxacin-tetracycline-containing quadruple group
Arm Type
Experimental
Arm Description
patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
Arm Title
tinidazole-tetracycline-containing quadruple group
Arm Type
Active Comparator
Arm Description
patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
Intervention Type
Drug
Intervention Name(s)
Levofloxacin
Intervention Description
levofloxacinn-tetracycline-containing quadruple regimens
Intervention Type
Drug
Intervention Name(s)
tinidazole
Intervention Description
tinidazole-tetracycline-containing quadruple regimens
Primary Outcome Measure Information:
Title
Eradication rates in 2 groups
Description
Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
The rate of improving dyspepsia symptoms after Helicobacter pylori eradication
Description
Dyspepsia symptoms will be measured using a 8-point Likert scale, and patients rate their symptoms from 0 (none) to 8 (severe) before and after the Helicobacter pylori eradication.
Time Frame
24 months
Title
The rate of adverse events happening
Description
Similarly, adverse events will also be measured by the Likert scale.
Time Frame
24 months
Title
The rate of good compliance
Description
Patients taken over 90% of drugs are considered to have a good compliance.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18-70 with H. pylori infection. Patients Allergic to Penicillin. Exclusion Criteria: Patients with previous H. pylori eradication therapy. Patients treated with Histamine-receptor antagonist, proton pump inhibitor, bismuth and antibiotics in the previous 4 weeks. Patients with gastrectomy, acute gastrointestinal bleeding and advanced gastric cancer. Patients with known or suspected allergy to study medications. Currently pregnant or lactating. Inability to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiuli Zuo, PhD,MD
Phone
15588818685
Ext
053188369277
Email
zuoxiuli@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiuli Zuo, PhD,MD
Organizational Affiliation
Qilu Hospital of Shandong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Qilu hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiuli Zuo, PhD,MD
Phone
15588818685
Ext
053188369277
Email
zuoxiuli@sina.com
First Name & Middle Initial & Last Name & Degree
Xiuli Zuo, PhD,MD
First Name & Middle Initial & Last Name & Degree
Minjuan Lin

12. IPD Sharing Statement

Learn more about this trial

Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin

We'll reach out to this number within 24 hrs